PRESS RELEASE
12 September 2023 07:00:00 CEST

Egetis to participate at medical conferences to increase disease awareness about MCT8 deficiency

Stockholm, Sweden, September 12, 2023. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced that the Company, as part of its initiatives to increase disease awareness about MCT8 deficiency, will participate at the following medical conferences during the remainder of 2023:

45th Annual Meeting of the ETA (European Thyroid Association)
September 10-13, 2023 in Milan, Italy

60th ESPE Annual Meeting (European Society of Pediatric Endocrinology)
September 21-23, 2023 in The Hague, The Netherlands

92nd Annual Meeting of the American Thyroid Association
September 27- October 1, 2023 in Washington DC, USA

CNS – 52nd Child Neurology Society Annual Meeting
October 4-7, 2023 in Vancouver, BC, Canada

Recently, the Company also presented a poster at the
SSIEM - Society for the Study of Inborn Errors of Metabolism
August 29- September 1, 2023 in Jerusalem, Israel
The poster entitled *"Landscape of genetic testing for monocarboxylate transporter 8 (MCT8) deficiency"* can be found here.

For further information, please contact:

Nicklas Westerholm, CEO
+46 (0) 733 542 062
nicklas.westerholm@egetis.com

Karl Hård, Head of Investor Relations & Business Development
+46 (0) 733 011 944
karl.hard@egetis.com

PRESS RELEASE
12 September 2023 07:00:00 CEST

About Egetis Therapeutics

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.
The Company's lead drug candidate *Emcitate* is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) *Emcitate* has shown highly significant and clinically relevant results on serum thyroid hormone T3 levels and secondary clinical endpoints. As a result of regulatory interaction Egetis intends to submit a marketing authorisation application (MAA) for *Emcitate* to the European Medicines Agency (EMA) on October 9, 2023, based on existing clinical data. After a dialogue with the FDA, Egetis is conducting a small randomized, placebo-controlled pivotal study in 16 patients to verify the results on T3 levels seen in previous clinical trials and publications. Egetis intends to submit a new drug application (NDA) in the US for *Emcitate* in mid 2024 under the Fast-Track Designation granted by FDA.
Emcitate holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. *Emcitate* has been granted Rare Pediatric Disease Designation (RPDD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval. This voucher can be transferred or sold to another sponsor.
The drug candidate *Aladote* is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study with the purpose of applying for market approval in the US and Europe for *Aladote* has been finalized after completed interactions with FDA, EMA and MHRA and study start is planned after *Emcitate* submissions have been completed. *Aladote* has been granted ODD in the US and in the EU.
Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see www.egetis.com

Attachments

Egetis to participate at medical conferences to increase disease awareness about MCT8 deficiency